Diazoxide-responsive hyperinsulinaemic hypoglycaemia in tyrosinaemia type 1
Open Access
- 11 January 2021
- journal article
- research article
- Published by Bioscientifica in Endocrinology, Diabetes & Metabolism Case Reports
- Vol. 2021 (1)
- https://doi.org/10.1530/edm-20-0174
Abstract
Summary Tyrosinaemia type 1 (TT1) is a rare inherited disorder of amino acid metabolism typically presenting with liver failure and renal tubular dysfunction. We describe three individuals with TT1 and transient hyperinsulinaemic hypoglycaemia (HH). Two siblings with TT1 and acute liver dysfunction were diagnosed with hyperinsulinaemic hypoglycaemia in the neonatal period. Both siblings were successfully treated with diazoxide/chlorthiazide and treatment was gradually weaned and stopped after 8 and 6 months of age respectively. The third patient presented with a neonatal liver failure with mild cholestasis, coagulopathy, fundus haemorrhages, vitamin A and E deficiency and hyperinsulinaemic hypoglycaemia. He maintained euglycaemia on high dose diazoxide (5–12 mg/kg/day) but developed pulmonary hypertension at 12 weeks of age. After discontinuation of diazoxide, he continued maintaining his blood glucose (BG) within the normal range. Although histological abnormalities of the pancreas including beta-cell hyperplasia are well documented, the exact mechanism of excessive insulin secretion in TT1 is not well understood. It may be related to the accumulation of toxic metabolites in the target organs including pancreas. Therefore, in patients with TT1 and persistent hypoglycaemia beyond the recovery of the acute liver failure, it is important to exclude hyperinsulinism which is usually transient and can be successfully treated with diazoxide and chlorothiazide. Further studies are required to determine which factors contribute to excessive insulin secretion in patients with TT1. Learning points Abstract Summary Tyrosinaemia type 1 (TT1) is a rare inherited disorder of amino acid metabolism typically presenting with liver failure and renal tubular dysfunction. We describe three individuals with TT1 and transient hyperinsulinaemic hypoglycaemia (HH). Two siblings with TT1 and acute liver dysfunction were diagnosed with hyperinsulinaemic hypoglycaemia in the neonatal period. Both siblings were successfully treated with diazoxide/chlorthiazide and treatment was gradually weaned and stopped after 8 and 6 months of age respectively. The third patient presented with a neonatal liver failure with mild cholestasis, coagulopathy, fundus haemorrhages, vitamin A and E deficiency and hyperinsulinaemic hypoglycaemia. He maintained euglycaemia on high dose diazoxide (5–12 mg/kg/day) but developed pulmonary hypertension at 12 weeks of age. After discontinuation of diazoxide, he continued maintaining his blood glucose (BG) within the normal range. Although histological abnormalities of the pancreas including beta-cell hyperplasia are well documented, the exact mechanism of excessive insulin secretion in TT1 is not well understood. It may be related to the accumulation of toxic metabolites in the target organs including pancreas. Therefore, in patients with TT1 and persistent hypoglycaemia beyond the recovery of the acute liver failure, it is important to exclude hyperinsulinism which is usually transient and can be successfully treated with diazoxide and chlorothiazide. Further studies are required to determine which factors contribute to excessive insulin secretion in patients with TT1. Learning pointsKeywords
This publication has 10 references indexed in Scilit:
- Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1Pediatric Drugs, 2019
- Diazoxide‐induced pulmonary hypertension in hyperinsulinaemic hypoglycaemia: Recommendations from a multicentre study in the United KingdomClinical Endocrinology, 2019
- Current and Emerging Agents for the Treatment of Hypoglycemia in Patients with Congenital HyperinsulinismPediatric Drugs, 2019
- Therapies and outcomes of congenital hyperinsulinism‐induced hypoglycaemiaDiabetic Medicine, 2018
- Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendationsGenetics in Medicine, 2017
- Hyperinsulinism in tyrosinaemia type IJournal of Inherited Metabolic Disease, 2004
- Visceral pathology of hereditary tyrosinemia type I.1990
- Tyrosinemia associated with hypermethioninemia and islet cell hyperplasia.1967
- Secondary metabolic derangements in patients with tyrosyluria.1967
- Tyrosinosis. A study of 6 cases.Archives of Disease in Childhood, 1966